Quantum-Si Showcases Technology Advancements at VIB Conference on Next-Generation Protein Analysis and Detection

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

Quantum-Si demonstrates a pathway to enable >70% coverage of the human proteome and identification of up to 90% of proteins, including post-translational modifications

Company continues to advance core technology as it moves towards commercialization of its Platinum™ protein sequencing platform later this year

GUILFORD, Conn.–(BUSINESS WIRE)– June 1, 2022 — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si”, “QSI” or the “Company”), a life sciences company marketing single-molecule protein sequencing, announced that Brian Reed, Ph.D., head of research at Quantum-Si, presented an update on the company’s technological advances at the Next-Generation Protein Analysis and Detection, a VIB Tools & Technologies conference, in Ghent, Belgium. The presentation is available in the Investors section of the Quantum-Si website under Events and Presentations.

Dr. Reed discussed progress in Quantum-Si research and development, including the expansion of the technology to interrogate more of the human proteome and its estimated 1,000,000+ proteoforms. This is essential for researchers to better understand how protein changes affect disease states. Reed also provided an overview of Quantum-Si’s protein sequencing technology platform, including Platinum™, which uses a proprietary and novel approach called Time Domain Sequencing™ to accurately decode the order of amino acids in a protein and interrogate changes for identification of a new drug. diagnostic targets and biomarkers. The ability to directly sequence proteins from a variety of sample types will generate new applications in disciplines such as oncology, neurology and cardiology.

“We have invested heavily in protein engineering and directed evolution approaches to accelerate the development of amino acid recognizers and increase the proportion of the proteome that we can detect,” Reed said. “To date, we have made significant progress towards commercial launch, having now demonstrated successful on-chip recognition of 15 of the 20 amino acids. These 15 amino acids represent a pathway to more than 70% coverage of the human proteome, identification of up to 90% of proteins, as well as a better understanding of protein sequence variation and post-translational modifications. Future developments of the platform will increase the accessibility of proteomics studies and enable new discoveries in biological and clinical research.

To learn more about Quantum-Si’s technology, download the company’s latest white paper, “Digitizing Protein Sequencing: Detection of Individual Amino Acids by Real-Time Photon Emission,” here.

About Quantum-Si Incorporated

Quantum-Si is focused on revolutionizing the burgeoning field of proteomics. The company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and digitize proteomics research to advance drug discovery and diagnostics across the world. beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates and projections and, therefore, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “expect”, “anticipate”, “intend”, “plan”, “may”, “will” , “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions (or negative versions of such words or expressions) are intended to identify such forward-looking statements. Such statements forward-looking statements include, but are not limited to, the Company’s expectations regarding future performance and the development and commercialization of products and services.These forward-looking statements involve significant risks and uncertainties that could cause actual results actual results differ materially from those discussed in the forward-looking statements. Many of these factors are beyond the control of the Company and are difficult to predict. Factors that could cause such differences include, but are not limited to: the impact of COVID-19 on Company activities; the inability to maintain the listing of the Company’s Class A common stock on the Nasdaq stock market; the ability to recognize the expected benefits of the recently completed business combination, which may be affected by, among other things, competition and the Company’s ability to grow and manage growth profitably and retain key employees; our ongoing leadership transition; changes in applicable laws or regulations; the Company’s ability to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the attributes and potential benefits of the Company’s products and services; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved products; the Company’s ability to identify, license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacturing and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or marketing of products and services that the Company develops; the size and growth potential of markets for the Company’s future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s products and services after the planned commercial launch; the Company’s estimates of future expenses, future revenues, capital needs and additional financing needs; the financial performance of the Company; and other risks and uncertainties described under “Risk Factors” in the Company’s Annual Report for the fiscal year ended December 31, 2021 and in the Company’s other filings with the SEC. The Company cautions that the above list of factors is not exclusive. The Company cautions readers not to place undue reliance on forward-looking statements, which speak only as of the date made. The Company neither undertakes nor accepts any obligation or undertaking to issue updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances about which any such statement is made. based.


Juan Avendano

Mike Cavanaugh

[email protected]


Karen Chase

[email protected]

Source: Quantum-Si Incorporated

Comments are closed.